Literature DB >> 22139498

Serum 'free' copper in Wilson disease.

J M Walshe1.   

Abstract

BACKGROUND: The relationship between serum 'free' copper and urine copper in patients with Wilson disease has not been explored. AIM: The object of this study is to ascertain if there is a direct relationship between these two parameters.
METHOD: The case notes of 320 patients with Wilson disease, seen between 1960 and 1987, have been reviewed. Eighty of these patients had received no treatment before referral and the results of serum 'free' copper and urine copper on admission and at one year of treatment have been analysed.
RESULTS: Except for patients with acute haemolysis, the ratio between 'free' serum copper and urine copper before treatment, on average, is around 7:1, after treatment this falls to around 5:1. But results show a wide scatter and there is no direct linear relationship.
CONCLUSION: The term 'free' copper is misleading and should be replaced by the more cumbersome but accurate term 'noncaeruloplasmin bound copper'. Most 'free' copper is complexed to albumin and is only available for excretion if there is significant protein loss by the kidneys.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22139498     DOI: 10.1093/qjmed/hcr229

Source DB:  PubMed          Journal:  QJM        ISSN: 1460-2393


  8 in total

1.  Measurement of urinary copper excretion after 48-h d-penicillamine cessation as a compliance assessment in Wilson's disease.

Authors:  Karolina Dzieżyc; Tomasz Litwin; Grzegorz Chabik; Anna Członkowska
Journal:  Funct Neurol       Date:  2015 Oct-Dec

Review 2.  A review and current perspective on Wilson disease.

Authors:  Mallikarjun Patil; Keyur A Sheth; Adarsh C Krishnamurthy; Harshad Devarbhavi
Journal:  J Clin Exp Hepatol       Date:  2013-07-06

3.  Copper phenotype in Alzheimer's disease: dissecting the pathway.

Authors:  Rosanna Squitti; Renato Polimanti
Journal:  Am J Neurodegener Dis       Date:  2013-06-21

4.  Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson's Disease Rating Scale.

Authors:  Anna Członkowska; Tomasz Litwin; Karolina Dzieżyc; Michal Karliński; Johan Bring; Carl Bjartmar
Journal:  BMC Neurol       Date:  2018-04-05       Impact factor: 2.474

Review 5.  Apoceruloplasmin: Abundance, Detection, Formation, and Metabolism.

Authors:  Maria C Linder
Journal:  Biomedicines       Date:  2021-02-25

6.  Bis-choline tetrathiomolybdate prevents copper-induced blood-brain barrier damage.

Authors:  Sabine Borchard; Stefanie Raschke; Krzysztof M Zak; Carola Eberhagen; Claudia Einer; Elisabeth Weber; Sandra M Müller; Bernhard Michalke; Josef Lichtmannegger; Albrecht Wieser; Tamara Rieder; Grzegorz M Popowicz; Jerzy Adamski; Martin Klingenspor; Andrew H Coles; Ruth Viana; Mikkel H Vendelbo; Thomas D Sandahl; Tanja Schwerdtle; Thomas Plitz; Hans Zischka
Journal:  Life Sci Alliance       Date:  2021-12-02

7.  Secretion and uptake of copper via a small copper carrier in blood fluid.

Authors:  B D Gioilli; T Z Kidane; H Fieten; M Tellez; M Dalphin; A Nguyen; K Nguyen; M C Linder
Journal:  Metallomics       Date:  2022-03-25       Impact factor: 4.526

Review 8.  Metal and complementary molecular bioimaging in Alzheimer's disease.

Authors:  Nady Braidy; Anne Poljak; Christopher Marjo; Helen Rutlidge; Anne Rich; Tharusha Jayasena; Nibaldo C Inestrosa; Perminder Sachdev
Journal:  Front Aging Neurosci       Date:  2014-07-15       Impact factor: 5.750

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.